# EDGAR Filing Document

**Accession Number:** 0002029039
**File Stem:** 0001493152-26-008780
**Filing Date:** 2026-3
**Character Count:** 2720
**Document Hash:** e57b94614d2d92f7e70c7ae19a54a4ff
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-008780.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0001493152-26-008780

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260304

**FILED AS OF DATE**: 20260304

**DATE AS OF CHANGE**: 20260304

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nasus Pharma Ltd
- **CENTRAL INDEX KEY:** 0002029039
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 516022712
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42796
- **FILM NUMBER:** 26718886

**BUSINESS ADDRESS:**
- **STREET 1:** 29 HARAKEVET ST
- **CITY:** TEL AVIV - YAFO
- **STATE:** L3
- **ZIP:** 6618003
- **BUSINESS PHONE:** 972 54-255-3956

**MAIL ADDRESS:**
- **STREET 1:** 29 HARAKEVET ST
- **CITY:** TEL AVIV - YAFO
- **STATE:** L3
- **ZIP:** 6618003

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of March 2026** 

**Commission File Number: 001-42796**

**Nasus Pharma Ltd.**

**Yigal Alon 65**

**Tel Aviv, Israel 6744317**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**<u>CONTENTS</u>**

On March 4, 2026, Nasus Pharma Ltd. (the "Company") announced that, due to the security situation in the State of Israel and restrictions on public gatherings, the location of the Company's Special General Meeting of Shareholders (the "Meeting") has been changed to a virtual meeting format only.

Shareholders will not be able to attend the Meeting in person. As previously announced by the Company in its Report of Foreign Private Issuer on Form 6-K on January 29, 2026, the Meeting will be held on Thursday, March 5, 2026 at 2:00 p.m. Israel time. Shareholders may attend the Meeting virtually at:

● Link: <u>https://zoom.us/j/94874269962?pwd=OWuiu8uqYLCInuxNe5vRg2w2BiqziZ.1</u> 

● Meeting ID: 948 7426 9962

● Passcode: 229406

**<u>SIGNATURE</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **NASUS PHARMA LTD.** | **NASUS PHARMA LTD.** |
| Date: March 4, 2026 | By: | */s/ Dan Teleman* |
|  | Name: | Dan Teleman |
|  | Title: | Chief Executive Officer |

---